MX2018012866A - Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion. - Google Patents

Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion.

Info

Publication number
MX2018012866A
MX2018012866A MX2018012866A MX2018012866A MX2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A MX 2018012866 A MX2018012866 A MX 2018012866A
Authority
MX
Mexico
Prior art keywords
expression
methods
compositions
antibodies based
making antibodies
Prior art date
Application number
MX2018012866A
Other languages
English (en)
Inventor
Chen Gang
Babb Robert
Burakov Darya
P Fandl James
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018012866A publication Critical patent/MX2018012866A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a la integración específica de sitio y la expresión de proteínas recombinantes en células eucariotas. En particular, la invención incluye composiciones y métodos para la expresión mejorada de anticuerpos lo que incluye anticuerpos biespecíficos en células eucariotas, particularmente líneas celulares de hámster chino (Cricetulus griseus), mediante el uso de un locus potenciador de la expresión.
MX2018012866A 2016-04-20 2017-04-20 Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion. MX2018012866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325385P 2016-04-20 2016-04-20
PCT/US2017/028552 WO2017184831A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Publications (1)

Publication Number Publication Date
MX2018012866A true MX2018012866A (es) 2019-03-11

Family

ID=58701850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012866A MX2018012866A (es) 2016-04-20 2017-04-20 Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion.

Country Status (15)

Country Link
US (2) US11530277B2 (es)
EP (1) EP3445780A1 (es)
JP (2) JP7134868B2 (es)
KR (2) KR102474757B1 (es)
CN (2) CN116004544A (es)
AR (1) AR108295A1 (es)
AU (1) AU2017253240A1 (es)
BR (1) BR112018071285A2 (es)
CA (1) CA3015371A1 (es)
EA (1) EA201892137A1 (es)
IL (2) IL262268B1 (es)
MX (1) MX2018012866A (es)
SG (2) SG10202010156XA (es)
TW (1) TW201803981A (es)
WO (1) WO2017184831A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210002669A1 (en) * 2017-12-22 2021-01-07 Genentech, Inc. Targeted integration of nucleic acids
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
KR102559149B1 (ko) * 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CA3123448A1 (en) * 2018-12-21 2020-06-25 Genentech, Inc. Targeted integration of nucleic acids
JP7250950B2 (ja) * 2019-03-29 2023-04-03 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットを標的指向組込みすることによってＦｃＲｎ発現細胞を作製するための方法
US20220170047A1 (en) 2019-04-02 2022-06-02 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
MX2021015536A (es) 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa proteina mediante integracion dirigida usando acido ribonucleico mensajero (arnm) de cre.
JP2022537338A (ja) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットの標的指向性組込みによって二価二重特異性抗体発現細胞を作製するための方法
MX2021015540A (es) * 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
MX2021015537A (es) 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
EP3986924A1 (en) * 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
TW202342755A (zh) * 2021-12-22 2023-11-01 美商建南德克公司 多載體重組酶介導的匣式交換

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
JP4817657B2 (ja) 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム
AU2003298674A1 (en) 2002-11-14 2004-06-15 Genentech Inc Intron fusion construct and method of using for selecting high-expressing production cell lines
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
JP2010514416A (ja) 2006-12-21 2010-05-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規な方法
US20080216185A1 (en) 2007-01-19 2008-09-04 Invitrogen Corporation Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CA2764370C (en) 2009-06-02 2018-08-21 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
AU2010265933B2 (en) 2009-06-26 2015-05-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI675044B (zh) 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2965495C (en) 2014-10-23 2022-05-24 Regeneron Pharmaceuticals, Inc. Cho integration sites and uses thereof
IL258036B (en) 2015-09-23 2022-09-01 Regeneron Pharma Optimized bispecific antibodies against class 3 determinants and their uses

Also Published As

Publication number Publication date
EA201892137A1 (ru) 2019-03-29
CN109071633A (zh) 2018-12-21
BR112018071285A2 (pt) 2019-02-12
CA3015371A1 (en) 2017-10-26
CN109071633B (zh) 2022-11-18
US11530277B2 (en) 2022-12-20
SG10202010156XA (en) 2020-11-27
KR20210135340A (ko) 2021-11-12
JP2019514358A (ja) 2019-06-06
TW201803981A (zh) 2018-02-01
US20190263937A1 (en) 2019-08-29
JP7134868B2 (ja) 2022-09-12
AR108295A1 (es) 2018-08-08
AU2017253240A1 (en) 2018-09-20
KR102474757B1 (ko) 2022-12-07
JP2022164824A (ja) 2022-10-27
CN116004544A (zh) 2023-04-25
WO2017184831A1 (en) 2017-10-26
EP3445780A1 (en) 2019-02-27
KR20180134894A (ko) 2018-12-19
US20230322956A1 (en) 2023-10-12
IL262268B1 (en) 2024-01-01
IL309065A (en) 2024-02-01
SG11201807881VA (en) 2018-10-30
IL262268A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX2018012866A (es) Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion.
MX2018012868A (es) Composiciones y metodos para generar anticuerpos basado en el uso de loci potenciadores de expresion.
PH12018501456A1 (en) Chimeric proteins and methods of regulating gene expression
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2021014712A (es) Polipeptidos de transposasa y sus usos.
AU2018397910A1 (en) Nucleic acid-containing lipid nano-particle and use thereof
MX2019006286A (es) Metodos para determinar la dosificacion en la terapia celular.
MX2017009153A (es) Proteinas de fusion de citoquinas.
EA201791275A1 (ru) Способы получения ctp-модифицированных полипептидов длительного действия
MY183188A (en) Non-human animals having a humanized b-cell activating factor gene
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
EA201892588A1 (ru) Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации
EA201791918A1 (ru) Модификация белков клеток-хозяев
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
MX2020002903A (es) Método para potenciar la expresión de arn en una célula.
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
TN2016000140A1 (en) Recombinant glycoproteins and uses thereof.
WO2016011448A3 (en) Methods and compositions for expression of polypeptides in a cell
TW202415767A (zh) 基於使用增強表現基因座之製備抗體的組成物及方法
EP3610888A4 (en) ANTIBODIES BINDING SPECIFICALLY TO THE N-TERMINAL REGION OF LYSYL-ARNT SYNTHETASE EXPOSED ON A CELLULAR MEMBRANE
WO2017079656A3 (en) Artificial proteins and compositions and methods thereof